Amneal Pharmaceuticals, Inc. 4

Director Gautam Patel reported RSU vesting and a stock award that together increased his direct holdings of Amneal Pharmaceuticals, Inc. Class A Common Stock, with 34,819 RSUs converting into shares and a separate 19,824-share award granted at no cost.

On this Form 4, reporting person Gautam Patel of Amneal Pharmaceuticals, Inc. reported the vesting and settlement of 34,819 restricted stock units (RSUs) into Class A Common Stock on May 7, 2026, with the underlying shares moving from derivative (RSUs) to non-derivative common stock ownership and no exercise price indicated, implying no cash outlay. In addition, on May 6, 2026, he received a new grant of 19,824 shares of Class A Common Stock (likely in the form of a stock award) at no stated cost, increasing his direct holdings. After these transactions, Patel directly owns 1,643,963 shares of Class A Common Stock, and the RSU balance associated with the 34,819-unit grant has been settled into shares. The Form 4 describes the RSUs as each representing a contingent right to receive one share of Class A Common Stock and notes that the 34,819-unit award was granted on May 6, 2025 and vested on May 7, 2026, in line with the issuer’s standard vesting terms tied to the annual meeting and one-year anniversary.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032922

Alert Tier

5